Novartis strikes radiopharma deal with Ratio worth up to $745Mnews2024-11-18T13:00:29+00:00November 18th, 2024|Endpoints News|
Exclusive: Athena Countouriotis’ Avenzo taps Shanghai biotech for ADC, adds new fundsnews2024-11-18T12:00:27+00:00November 18th, 2024|Endpoints News|
Evotec gains on Halozyme’s takeover proposalnews2024-11-15T12:16:40+00:00November 15th, 2024|Endpoints News|
European Commission seeks biopharma feedback on Novo-Catalent deal — reportnews2024-11-14T17:55:02+00:00November 14th, 2024|Endpoints News|
Merck buys into PD-1/VEGF space as Summit comes for Keytrudanews2024-11-14T12:29:52+00:00November 14th, 2024|Endpoints News|
Otsuka and ICU Medical forge IV manufacturing network to supply the USnews2024-11-13T14:15:19+00:00November 13th, 2024|Endpoints News|
BioNTech buys out partner Biotheus for PD-L1/VEGF cancer drugnews2024-11-13T11:45:55+00:00November 13th, 2024|Endpoints News|
Roche teams with Flare Therapeutics on transcription factorsnews2024-11-12T12:00:35+00:00November 12th, 2024|Endpoints News|
Novartis pays $150M upfront to Schrödinger in new drug dealnews2024-11-12T11:50:06+00:00November 12th, 2024|Endpoints News|
GSK acquires Parkinson’s small molecule from Vesaliusnews2024-11-12T11:30:30+00:00November 12th, 2024|Endpoints News|
